Global Information
회사소개 | 문의

1형 당뇨병(소아 당뇨병) : 파이프라인 리뷰

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 232787
페이지 정보 영문 576 Pages
가격
US $ 2,500 ₩ 2,822,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,644,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,466,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


1형 당뇨병(소아 당뇨병) : 파이프라인 리뷰 Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018
발행일: 2018년 05월 페이지 정보 : 영문 576 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

1형 당뇨병(소아 당뇨병)은 췌장이 인슐린 생산을 중단하는 자가면역질환입니다. 인슐린에 의해 사람은 음식으로부터 에너지를 얻을 수 있습니다. 인체 면역계가 췌장 내부의 인슐린 생산세포(β세포)를 공격·파괴하여 발병합니다. 주요 질병 소질로서 선천성 질환과 가족력, 췌장질환, 감염증 등을 들 수 있습니다. 주요 징후와 증상으로는 심각한 갈증과 잦은 요의, 극도의 공복감, 체중 감소, 권태감, 화, 비일상적 행동 등을 들 수 있습니다.

세계의 1형 당뇨병(소아 당뇨병) 치료제 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

1형 당뇨병(소아 당뇨병) 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of Type1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of Type1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type1 diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 11, 33, 29, 2, 102, 32 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 30 and 4 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Type1 diabetes (Juvenile Diabetes) - Overview
  • Type1 diabetes (Juvenile Diabetes) - Therapeutics Development
  • Type1 diabetes (Juvenile Diabetes) - Therapeutics Assessment
  • Type1 diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  • Type1 diabetes (Juvenile Diabetes) - Drug Profiles
  • Type1 diabetes (Juvenile Diabetes) - Dormant Projects
  • Type1 diabetes (Juvenile Diabetes) - Discontinued Products
  • Type1 diabetes (Juvenile Diabetes) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co KG, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by apceth Biopharma GmbH, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Apodemus AB, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Arecor Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLineRx Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Biozeus, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Boston Therapeutics Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by BTB Pharma AB, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Cellix Bio Pvt Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by DanDrit Biotech A/S, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Denceptor Therapeutics Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by DiaVacs Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici SpA, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Co, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by EpiVax Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corp, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Geropharm LLC, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by ImCyse SA, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corp, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Just Biotherapeutics Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Pvt Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals Inc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by MannKind Corp, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Maruho Co Ltd, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Medtronic Plc, H1 2018
  • Type1 diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc, H1 2018

List of Figures

  • Number of Products under Development for Type1 diabetes (Juvenile Diabetes), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research